» Articles » PMID: 35485206

A Novel EHD1/CD44/Hippo/SP1 Positive Feedback Loop Potentiates Stemness and Metastasis in Lung Adenocarcinoma

Overview
Journal Clin Transl Med
Publisher Wiley
Specialty General Medicine
Date 2022 Apr 29
PMID 35485206
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is growing evidence that endocytosis plays a pivotal role in cancer metastasis. In this study, we first identified endocytic and metastasis-associated genes (EMGs) and then investigated the biological functions and mechanisms of EMGs.

Methods: Cancer stem cells (CSCs)-like characteristics were evaluated by tumour limiting dilution assays, three-dimensional (3D) spheroid cancer models. Microarray analysis was used to identify the pathways significantly regulated by mammalian Eps15 homology domain protein 1 (EHD1) knockdown. Mass spectrometry (MS) was performed to identify EHD1-interacting proteins. The function of EHD1 as a regulator of cluster of differentiation 44 (CD44) endocytic recycling and lysosomal degradation was determined by CD44 biotinylation and recycling assays.

Results: EHD1 was identified as a significant EMG. Knockdown of EHD1 suppressed CSCs-like characteristics, epithelial-mesenchymal transition (EMT), migration and invasion of lung adenocarcinoma (LUAD) cells by increasing Hippo kinase cascade activation. Conversely, EHD1 overexpression inhibited the Hippo pathway to promote cancer stemness and metastasis. Notably, utilising MS analysis, the CD44 protein was identified as a potential binding partner of EHD1. Furthermore, EHD1 enhanced CD44 recycling and stability. Indeed, silencing of CD44 or disruption of the EHD1/CD44 interaction enhanced Hippo pathway activity and reduced CSCs-like traits, EMT and metastasis. Interestingly, specificity protein 1 (SP1), a known downstream target gene of the Hippo-TEA-domain family members 1 (TEAD1) pathway, was found to directly bind to the EHD1 promoter region and induce its expression. Among clinical specimens, the EHD1 expression level in LUAD tissues of metastatic patients was higher than that of non-metastatic patients.

Conclusions: Our findings emphasise that EHD1 might be a potent anti-metastatic target and present a novel regulatory mechanism by which the EHD1/CD44/Hippo/SP1 positive feedback circuit plays pivotal roles in coupling modules of CSCs-like properties and EMT in LUAD. Targeting this loop may serve as a remedy for patients with advanced metastatic LUAD.

Citing Articles

Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters.

Que Z, Qi D, Yang Y, Yao W, Liu J, Li Y Cell Mol Biol Lett. 2025; 30(1):23.

PMID: 39994505 PMC: 11849222. DOI: 10.1186/s11658-025-00696-9.


The MIR181A2HG/miR-5680/VCAN-CD44 Axis Regulates Gastric Cancer Lymph Node Metastasis by Promoting M2 Macrophage Polarization.

Zang W, Yang Y, Chen J, Mao Q, Xue W, Hu Y Cancer Med. 2025; 14(2):e70600.

PMID: 39823128 PMC: 11739459. DOI: 10.1002/cam4.70600.


SP1 undergoes phase separation and activates RGS20 expression through super-enhancers to promote lung adenocarcinoma progression.

Shan L, Wang W, Du L, Li D, Wang Y, Xie Y Proc Natl Acad Sci U S A. 2024; 121(29):e2401834121.

PMID: 38976739 PMC: 11260144. DOI: 10.1073/pnas.2401834121.


Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.


Compartmentalization proteomics revealed endolysosomal protein network changes in a goat model of atrial fibrillation.

Ayagama T, Charles P, Bose S, Boland B, Priestman D, Aston D iScience. 2024; 27(6):109609.

PMID: 38827406 PMC: 11141153. DOI: 10.1016/j.isci.2024.109609.


References
1.
Crawford J, Bronner S, Zbieg J . Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. Expert Opin Ther Pat. 2018; 28(12):867-873. DOI: 10.1080/13543776.2018.1549226. View

2.
Leon G, MacDonagh L, Finn S, Cuffe S, Barr M . Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther. 2015; 158:71-90. DOI: 10.1016/j.pharmthera.2015.12.001. View

3.
Beishline K, Azizkhan-Clifford J . Sp1 and the 'hallmarks of cancer'. FEBS J. 2014; 282(2):224-58. DOI: 10.1111/febs.13148. View

4.
Misra J, Irvine K . The Hippo Signaling Network and Its Biological Functions. Annu Rev Genet. 2018; 52:65-87. PMC: 6322405. DOI: 10.1146/annurev-genet-120417-031621. View

5.
Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View